Pharming Group Faces Investor Scrutiny After Revenue Guidance Cut

The legal firm Levi & Korsinsky, operating under the SueWallSt brand, is currently probing whether Pharming Group and its executives issued misleading statements regarding the company's financial health. On May 7, 2026, during a first-quarter earnings call, management projected full-year revenue between $405 million and $425 million. By July 30, however, that forecast was lowered to a range of $375 million to $395 million.

This shift coincided with a disappointing second-quarter report, which revealed total revenue of $90.2 million—a 3% decline compared to the same period last year. Earnings also slipped, with diluted earnings per share dropping to $0.002 from $0.006. Analyst expectations had been significantly higher, with consensus estimates hovering near $419 million before the announcement. The investigation now seeks to determine if investors were provided with accurate information when purchasing shares at prices that were potentially inflated by the company's earlier, more optimistic guidance.